Drug
Denifanstat
Denifanstat is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(25%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_1
1
25%
Ph phase_3
2
50%
Ph phase_2
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Terminated(2)
Detailed Status
Withdrawn2
Completed1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 32 (50.0%)
Trials by Status
completed125%
active_not_recruiting125%
withdrawn250%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_2
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
NCT03179904
completedphase_1
A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants
NCT07216313
withdrawnphase_3
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH
NCT06692283
withdrawnphase_3
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
NCT06594523
Clinical Trials (4)
Showing 4 of 4 trials
NCT03179904Phase 2
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
NCT07216313Phase 1
A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants
NCT06692283Phase 3
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH
NCT06594523Phase 3
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4